PharmacovigilanceOfficial
Commission grants marketing authorisation for ensartinib product Gevalka to SFL Pharmaceuticals Deutschland
🇪🇺 European Commission (Union Register) · Mon 16 Nov 2026
Commission Decision (2026) 8320 of 16 November 2026 authorises Gevalka (ensartinib) in the EU, with SFL Pharmaceuticals Deutschland GmbH named as marketing authorisation holder.
The European Commission has granted a new marketing authorisation for Gevalka, whose active substance is ensartinib. The authorisation was issued through Commission Decision (2026) 8320 of 16 November 2026, and the holder is SFL Pharmaceuticals Deutschland GmbH.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Official source: European Commission (Union Register) ↗
Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.
More Pharmacovigilance
All →
AEMPS updates contraceptive advice for women taking tirzepatide with oral contraceptives
🇪🇸 AEMPS · Thu 19 Nov 2026
EEA Joint Committee amends Annex I on veterinary and phytosanitary matters
🇪🇺 EUR-Lex · Thu 19 Nov 2026
FDA early alert: Tablo power cord connections may overheat, Outset Medical updates instructions
🇺🇸 FDA MedWatch · Wed 18 Nov 2026
EMA publishes list of Union reference dates and PSUR submission frequencies
🇪🇺 EMA · Wed 18 Nov 2026
EU Health Security Committee urges stronger action on carbapenem-resistant bacteria as infections rise
🇪🇺 European Commission (DG SANTE) · Wed 18 Nov 2026
AIFA starts rolling review of daraxonrasib after positive CHMP opinion in pancreatic cancer
🇮🇹 AIFA · Wed 18 Nov 2026